Back to mobile site

Sarepta Therapeutics (SRPT) Lowers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. ALAR
3. SPY
4. PBA
5. CCH:LN
6. META
7. CCHGY
8. PRY:IM
9. PRYMY
10. SKA-B

May 6, 2025 4:19 PM EDT

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($3.42), $5.38 worse than the analyst estimate of $1.96. Revenue for the quarter came in at $774.9 million versus the consensus estimate of $695.9 million.

GUIDANCE:

Sarepta Therapeutics sees FY2025 revenue of $2.3-2.6 billion, versus the consensus of $3.07 billion.

2025 Financial Guidance

Updated Guidance

Prior Guidance

Assumptions

As of May 6, 2025

As of February 26, 2025

Total net product revenues

$2,300 - $2,600M

$2,900 - $3,100M

Reflects updated ELEVIDYS outlook

  • Represents +37% YoY growth at the midpoint of the revised range

Combined non-GAAP R&D and SG&A expenses

$1,784 - $2,184M

$1,200 - $1,300M

Consistent operating expense outlook from prior guidance, now includes Arrowhead collaboration:

  • Closing transaction costs ($584M)
  • Potential DM1 development milestone payments ($100-$300M)

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Guidance

Related Entities

Earnings, Maynard Um, Mark Zuckerberg, ARK